Latest News !
 

Ausbiotech, Biotech Daily: 'Don't Cut the 45% R&D Tax Incentive'
- Sep 13, 2016

Pro Medicus: The Roll-Out Has Just Begun - Aug 22, 2016 

Protagonist Raises $117m, Lists on Nasdaq For Peptide Drugs

10-Year BDI-40 Up 163%, ASX200 Up 3%, Big Caps Up 308%

Teva Returns Mesoblast Heart Drug; Equity Facility - Jun 14, 2016

Biotech Daily Policy On Mega-Day-Traders - May 3, 2016

2015 - The Year In Review

Novartis Buys Spinifex For $916m

Genetic Technologies Dr Mervyn Jacobson 12 Months Gaol

Gaol For The Phosphagenics Three: Dr Esra Ogru
Dr Robert Gianello, Dr Woei-Jia Jiang

BRIL Group Senate Innovation Submission:
Set Aside 25% Of $20bn MRFF For Commercialization

 

August BDI-40 Up 6% To Record $8.3b
ASX200 Down 2%, Big Caps Down 6%

Anteo Up 62%, Compumedics 43%, Acrux Down 49%, Actinogen 27%

 

September 1, 2016

 

Spring has certainly sprung for the Biotech Daily Top 40 Index (BDI-40) - up 5.9 percent in August to its highest collective market capitalization of $8,284 million.

 

The ASX200 fell 2.3 percent in August, the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) were down 5.8 percent, mostly attributable to CSL retreating 8.4 percent to $49,347 million, while Cochlear hit a record $8,073 million.

 

For the year to August 31, 2016, the BDI-40 was up 28.7 percent, the Big Caps were up a collective 21.1 percent and the ASX200 was up 4.3 percent.

 

In August, 21 of the BDI-40 companies were up, 10 by more than 10 percent, with 18 down and one unchanged.

 

Anteo was the best, recovering 61.9 percent to $68 million followed by Compumedics up $30 million or 42.9 percent to $100 million, Osprey (25.5%), Factor Therapeutics (20.0%), Airxpanders (19.8%), Mesoblast (19.7%), Pro Medicus (18.5), Living Cell (15.8%), Impedimed (15.4%) and Nanosonics (13.8%).

 

Acrux led the falls, down 49.2 percent to $62 million, followed by Actinogen (27.3%), Antisense (25.0%), Neuren (22.4%), Bionomics (19.0%), Opthea (17.5%), Atcor (15.4%), Genetic Technologies (12.9%), Medical Developments (12.7%) and Uscom (10.8%).

 

The Nasdaq Biotech Index fell 3.0 percent in August and was down 17.9 percent for the year to August 31, with former Australian company Heartware consumed by Medtronic, Aviragen (Biota) down 2.9 percent to $68 million, Sunshine Heart unchanged at $22 million and Israel’s Redhill, developing Giaconda’s assets, up 15.0 percent to $253 million.

 

Outside the BDI-40, Dorsavi returned to its peak market capitalization of $60 million, while Innate Immunotherapeutics and OBJ continued to strengthen.

 

Biotech Daily is undertaking a little Spring cleaning.

 

Airxpanders and Compumedics will be promoted into the Top 20 replacing Acrux and Universal Biosensors, with Cyclopharm, Dimerix and Genetic Signatures promoted into the BDI-40 replacing Antisense, Biotron and Genetic Technologies.

 

BDI-40 v S&P ASX200 Jun 30, 2006 to Aug 31, 2016 

 

 

BDI-40 v S&P ASX200 Aug 31, 2015 to Aug 31, 2016 

 

Big Caps (Cochlear, CSL, Resmed) Aug 31, 2015 to Aug 31, 2016